Major depression is one of the main factors contributing to the Global Burden of Disease. Current 16 treatment strategies (e.g., antidepressants and neurostimulation techniques) of major depression 17
Introduction
second most prevalent cause of illness-induced disability (1), which makes this disorder one of the 34 main contributors to the Global Burden of Disease (2) . It is generally treated with chronic 35 antidepressants (ADs), which consist of drugs increasing monoaminergic neurotransmission such 36 as selective serotonin reuptake inhibitors (SSRIs). However, nearly 65% of the patients do not 37 respond to this first-line therapy, and it is established that 30-50% of patients are resistant to AD 38 compounds (3, 4), which means they do not show remission after treatment with several ADs: this 39 condition is conventionally referred to as treatment resistant depression (TRD). Furthermore, MD 40 often presents itself with a high and disabling comorbidity to anxiety disorders, where SSRIs show 41 a less reliable spectrum of therapeutic efficacy (5). 42
In the past decade, progress in the treatment of TRD has involved neurostimulation, which consists 43 in activating/inhibiting the cerebral networks whose functioning is modified in MD. Regions of 44 interest include the dorsolateral prefrontal cortex (dlPFC), the subgenual part of the anterior 45 cingulate cortex (sgACC), the nucleus accumbens or the lateral habenula (6). While the dlPFC is 46 a cortical area that can be targeted using neurostimulation methods such as repeated transcranial 47 magnetic stimulation (rTMS) or direct current stimulation (DCS), the same does not apply to 48 deeper brain regions that can be targeted only using invasive approaches such as deep brain 49 stimulation (DBS). Therefore, there is an urgent need to develop novel and efficient 50 neurostimulation techniques that can target deep brain regions in a focal and non-invasive manner. 51 overall, the success rate of motor responses increased with pressure, though a total failure of motor 91 responses appeared at 50 kPa ( Figure 1B) . The motor threshold (MT, i.e. 50% success rate) 92 appeared at 250 kPa. High-success rates (>80%) were found from 350 kPa (81.5±3.9%) to 500 93 kPa (98.5±0.8%). The experimental data was fit into a sigmoidal curve that followed classical 94 dose-response relationship (26). High-success rates approaching the plateau of the curve (>350 95 kPa) were retained for further analysis. 96
The strength and reliability of high-success pressures were evaluated in a second subset of ten 97 distinct mice processed under deeper anesthesia (1% isoflurane) and implanted with subdermal 98 electrodes in the right brachioradialis muscle group (28). Electromyographic (EMG) recordings 99 revealed different strength and reliability of pressures ranging from 350 kPa to 500 kPa. A 100 significant peak average amplitude of motor evoked potentials (MEPs) was obtained at 400 kPa 101 (F(2,18)=13, p=0.0003), above 350 kPa (p=0.0026; Figure 1C ). A lower coefficient of variation 102 was also found at 400 kPa (relative standard deviation/RSD=32.4%) in comparison to lower or 103 higher-pressure steps (at 350 kPa, RSD=76.4%; see Table I ). The lateral resolution of the US beam 104 at 400 kPa was further estimated between 2.5 and 1 mm, showing greater interest for a focal 105 stimulation of the prefrontal cortex ( Figure 1D ). Based upon the overall data obtained from M1 106 stimulation, the optimal US parameters for single-pulse USNS were determined at 400 kPa (160-107 msec pulse length), displaying criteria of motor success (89±2.7%), strength (MEP=63.7±6.5 108 µVpp), reliability (RSD=32.4%) and focality (1-2.5 mm) compared to lower or higher-pressure 109 steps. 110 Electromyographic recordings (1% isoflurane) of motor responses for pressure steps above 80% motor success. (D) 117 Focality of the US beam at peak negative pressure 400 kPa (1 mm at 400 kPa, 2.5 mm from 350 kPa to 400 kPa). Figure 2B ). Otherwise, the activity index 139 was further increased in IL (2.67) and multiple analyses revealed that acute USNS elicited 140 significant c-Fos activity along antero-posterior axis of the structure (F(1,3)=14.6, p=0.032). At 141 distance from prefrontal structures, acute USNS did not evoke specific c-Fos activity in the 142 olfactory areas (OL) nor in the auditory cortex (Ad; Figure 2C ). In connected subcortical regions, 143 acute USNS induced significant c-Fos activity in subfields of the dorsal/ventral hippocampus 144 (Table II) . 145 
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Chronic repeated USNS treatment alleviates anxiety-related behaviors 161
The effects of chronic repeated USNS treatment was evaluated in the main cohort of fifty-three 162 mice subjected to the UCMS regimen from day 0 to day 35. At day 7, UCMS mice were 163 significantly different from non-stressed mice in terms of coat state deterioration, a standard 164 measure of UCMS onset and evolution (30) (Supplementary C); from this timepoint, UCMS mice 165 were semi-randomly distributed into the four following treatment/control groups. From day 29 to 166 day 33, chronic USNS (i.e. 5 sessions of acute USNS) was applied to fifteen mice while fourteen 167 mice followed a sham condition ("Sham"). From day 38 to day 43, mice were tested for depressive-168 like and anxiety-related behaviors in several paradigms. The effects of chronic USNS were 169 assessed against a classic AD compound (fluoxetine, "Flx"), administered chronically through 170 drinking water from day 7 on and controlled (vehicle, "Veh"; Figure 3A ). To provide ground 171 values, a group of twelve non-stressed, untreated mice ("Naive") were processed at the same age 172 through the same behavioral paradigms. 173
Overall, both treatments modified behaviors to a different extent. The ability for nest-building, a 174 daily-living measure classically affected by chronic stress (31, 32), was modified by treatments (F 175 (3, 49)=7.9, p=0.0002); chronic USNS mice built the nest faster than Sham mice (p=0.0005), 176
whereas Flx mice did not perform over Veh mice ( Figure 3B ). Mice were then tested for 177 depressive-like behaviors in a reward-maze paradigm, built of three successive chambers with a 178 palatable biscuit laid in the center of the furthest (30). The relative consumption of the reward, 179 depending on the latency to reach said reward, was modified by treatments (F (3, 49)=5. including the prelimbic/M2 area, but also in the orbitofrontal regions. In addition, chronic USNS 194 increased significantly the metabolic activity in distant subcortical regions such as the dorsal and 195 ventral striata, the thalamus, the dorsal part of the hippocampus, the periaqueductal gray matter 196 (PAG) and the raphe nuclei ( Figure 3E , Table III ). Other regions underneath the target (e.g., 197
anterior olfactory regions and dorsal peduncular cortex), did not display modified metabolic Chronic repeated USNS treatment modifies long-term metabolomics in cortical and 218 subcortical regions 219
Ten days pas the last chronic USNS session, significant modifications were found when compared 220 to Sham mice (n=8/group) in the metabolome of interconnected brain regions involved in the 221 UCMS model (23) and MD (6): the Cg, the prelimbic/infralimbic cortex (PrL/IL), the amygdala 222 and the hippocampus. 223
In cortical regions, chronic USNS had a relatively low impact on the metabolome of the Cg, since 224 no metabolic pathway was found significantly disturbed, despite 9 metabolites showing 225 significantly different concentrations compared to Sham mice (Table IV ). In the PrL/IL of chronic 226 USNS mice, 6 metabolites were significantly modified, including the decrease of glutamic 227 acid/glutamate concentrations (Table IV) . Five metabolic pathways were found disrupted, 228
including arginine-proline metabolism (false discovery rate (FDR)=7.8×10 -4 ), alanine metabolism, 229 aspartate and glutamate (FDR=0.016), glutathione metabolism (FDR=0.017), histidine 230 metabolism (FDR=0.024), glycine metabolism, serine and threonine (FDR=0.035) and aminoacyl-231 tRNA biosynthesis (FDR=0.038; Table V) . 232 
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In subcortical regions, the amygdala was impacted where 7 metabolites were found significantly 239 modified (Table VI) . Nine metabolic pathways were found significantly disturbed including 240 aminoacyl-tRNA biosynthesis (FDR=4.48×10 -5 ), abnormalities in lysine biosynthesis 241 In the hippocampus, 5 metabolites were found significantly modified (Table VI) . Five metabolic 243 pathways were also significantly disrupted including aminoacyl-tRNA biosynthesis 244 (FDR=2.16×10 -7 ), alanine-aspartate-glutamate and nitrogen metabolisms (FDR=0.004), arginine-245 proline metabolisms (FDR=0.013), and glutathione metabolism (FDR=0.023; Table VII ). Despite 246 long-term changes in the metabolome of the hippocampus, no effects of chronic USNS were found 247 on the proliferation of newborn neurons in the dentate gyrus of the hippocampus (DG), a key 248 mechanism to the function of classic ADs (Supplementary B 
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Discussion 256 Numerous brain structures are known actors in the pathophysiology of MD, yet the growing need 257 to act therapeutically on these regions remains only partially answered by current ADs and 258 neurostimulation techniques. The present study used repeated mechanical US waves to non-259 invasively target the IL/sgACC in a mouse model of MD. Chronic repeated USNS treatment 260 impacted various behavioral endpoints induced by the UCMS regimen, which was associated to 261 short-term changes in brain metabolic activity on the site of stimulation (prefrontal cortex and its 262 close surroundings) but also at distant, connected limbic regions, such as the striatum, the dorsal 263 hippocampus and the raphe nucleus. Measures of well-being (nest-building) and anxiety-related 264 behaviors (open-field task) were ameliorated by chronic USNS, while items relative to anhedonia 265 and reward-seeking were not readily modified compared to classic SSRI treatment (fluoxetine). 266
Metabolites were modified at long-term in cortical regions on target site and in subcortical regions 267 in the amygdala and the hippocampus, involving glutamate pathways that might correlate to 268 longer-term changes in brain plasticity. 269
The ability of US waves to reliably stimulate cortical regions through the cranium has been 270 reproduced in the current study with single-pulse USNS of the primary motor cortex M1. the current data reproduced previous findings in terms of the sigmoidal relationship of the pressure 272 to the motor success at low dose anesthesia (26), the quantitative analysis of MEPs showed that 273 the strength of the stimulation and its reliability over multiple stimulations might depend on other 274 factors than acoustic pressure alone. Consistent rising of motor success with acoustic pressure 275 points toward an activation of glutamatergic neurons, but the inconsistency of MEP amplitudes 276 with higher pressures (>400 kPa) could reflect the recruitment of different neural populations 277 depending on US parameters, even though desensitization biases were controlled with a 10-sec 278 spacing of US pulses (16). Such variations upon intensity/pulse length were observed for different 279 neurostimulation approaches (i.e. rTMS) and might apply to USNS (33, 34). Thus, the 280 determination of optimal US parameters in terms of pressure/pulse length appears pivotal to induce 281 reliable brain stimulation with US waves. Furthermore, the deeper anesthesia used during the MEP 282 procedure (1% isoflurane) could have modified the quality of motor signals at pressures above 400 283 kPa and so despite higher motor success rates at 0.1% isoflurane; the concentrations used in most 284 studies for MEP analysis (<0.25 %) were too low to fit those of the chronic USNS paradigm (1%), 285
where a semi-awoken state could impart anxiety biases. We thus reckoned that the current findings 286 at 1% isoflurane could be more readily transposed to the treatment condition of chronic USNS. 287
Concurrently, motor responses could be diminished by slow-moving cortical spreading 288 depolarization (14), occurring for lastly tested pressures (500 kPa), which further underpin the 289 need to finely tune US pulses in terms of intrinsic parameters and sustained effects (35). 290
When applied for one unique session, acute USNS was able to evoke neural activity in the IL of 291 mice with little spatial inaccuracy at stimulation site: surrounding brain regions such as the PrL or 292 the Cg, M2 and M1 were not readily affected by the stimulation in comparison to sham-treated 293 mice. On the other hand, distant hippocampus regions were affected by acute USNS. Given the 294 geometric properties of the US beam, the results suggest that, similarly to standard M1 stimulation, 295 a threshold pressure appears for patterns of repeated stimuli, under which the activation of a brain 296 region was not seen on immediate c-Fos labelling; the lack of c-Fos activation in other prefrontal 297 regions suggests that the spatial resolution of acute USNS is not directly correlated to its functional 298 resolution. The narrower range of effective acoustic pressures could be responsible for the specific 299 stimulation of the IL (1-mm wide at 400 kPa). Furthermore, the auditory cortex was not affected 300 by acute USNS, which further supports a functional targeting of the IL (36, 37). Because c-Fos 301 labelling does not discriminate between glutamatergic and GABAergic neurons, the results show 302 that brain regions might react differently to acute USNS. As pulsed neurostimulation is described 303 to preferentially act on axons rather than somas (38), the reactivity of a brain region to the 304 application of USNS might depend on the orientation of the stimulation and the frequency of pulse 305 repetition as it has been shown for rTMS (39), highlighting the discrepancy between geometric 306 and functional focality when applying repeated, sustained stimulation. 307
When applied chronically for 5 days, behavioral measures were modified by repeated USNS. As 308 an indicator of well-being in rodents, the onset of nest-building was reduced by chronic USNS, 309
while it was not affected by fluoxetine (similar effects of the drugs were previously reported (31)). 310
Because such daily-living activities can be negatively regulated by chronic stress and MD, chronic 311 USNS showed beneficial effects on this aspect of the UCMS model. Furthermore, chronic USNS 312 reduced anxiety-like behaviors: measures of mobility and center-crossings were found 313 significantly different from sham-treated mice in the open-field task. On the other hand, the 314 anhedonic measure of reward consumption was not ameliorated and did not match the results of 315 fluoxetine-treated mice. It was reported that a single session of isoflurane anesthesia could induce 316 antidepressant-like effects and increase glutamatergic transmission in the hippocampus (40), 317 however, the sham-treated group displayed baseline behaviors statistically equal to vehicle-treated 318 mice, suggesting that the present results are specific to the chronic USNS condition. As opposed 319 to fluoxetine, where a variability of anxiolytic effects is reported (5), chronic USNS might act 320 differently from classic SSRIs, involving top-down mechanisms of the prefrontal cortex over 321 subcortical regions. The high comorbidity of MD with anxiety disorders, further disabling for 322 patients, is not fully treated by classic SSRIs (5), , underpinning different therapeutic paths for 323 both anxiety and depressive-related symptoms. Classic AD compounds also show different effects 324 based upon the duration of administration, with a lower impact at an acute/sub-chronic stage of 325 medication (41). Furthermore, the current results show different levels of response to fluoxetine, 326 with bimodal distributions appearing in behavioral measures; this might reflect similar resistance 327 mechanisms observed in patients with MD, or the inadequacy of fluoxetine for some subjects. On 328 the other hand, chronic USNS mice displayed lower spread distributions, which could suggest that 329 the technique imparts beneficial effects independently from inter-individual variability and in a 330 shorter timespan following treatment. Finally, because anxiety-related and anhedonic features do 331 not rely on the same brain correlates, the anxiolytic effects of chronic USNS might appear early 332 following treatment. However, the antidepressant effects, although only slightly impacted, could 333 develop after a longer period and depending on long-term changes in metabolic activity. 334
The direct aftermath of chronic USNS was evaluated with microPET imaging 72 hours past the 335 last treatment session. The uptake of [ 18 F]-FDG was increased near the target site at bregma +2 336 mm in prefrontal regions (mostly the PrL and the orbitofrontal cortex (OFC)) and in M2. Because 337 this latter region cannot presently be linked to brain modifications induced by the UCMS regimen 338 and more broadly in MD, the increased activity might be a direct effect of chronic USNS, either 339 showing spatial biases or a different functional focality when repeated chronically as opposed to 340 acute USNS. Other regions within a 1.5-mm radius of the stimulation site did not appear modified 341 during microPET imaging, suggesting that presumably only the most intense portion of the US 342 beam acts upon the target also in this timespan. The brain metabolic activity was also increased in 343 distant regions (striatum, thalamus, dorsal hippocampus, raphe nucleus and PAG), which could 344 mean that chronic USNS acted at distance from the prefrontal target through functional 345 connectivity, which is supported by the effects of acute USNS on the hippocampus. Likewise, glutamate pathways were similarly modified in all studied regions, and more glutamate levels were reported to increase in the serum and in frontal regions of MD patients (46, 363 47). In rodents, glutamate is implicated in the expression of depressive-like and anxiety-related 364 behaviors (48). Furthermore, glutamate pathways in the hippocampus, but not the prefrontal 365 cortex, might be pivotal to antidepressant response in SSRI-treated mice (49). The current findings 366 thus show that the effects of chronic USNS on glutamate pathways could be associated to a 367 therapeutic response similarly to classic fluoxetine treatment, although both treatments did not 368 modify the same behaviors in the UCMS model. In addition, our results showed that other 369 hippocampal functions, such as neurogenesis, were not modified by chronic USNS, which further 370 supports that the behavioral effects were mainly observed on anxiety and not directly on anhedonic 371
features. In the present study, few metabolic modifications were found in the Cg of stimulated 372 mice, even though this structure was in the propagation path of the US beam during stimulation. 373
Direct interneuron regulation between the structures could have been at play and thus participated 374
in reversing prefrontal abnormalities induced by UCMS (20). Glutamate variations in other brain 375 regions, such as the PAG, have also been linked to depressive-like behaviors and chronic stress 376 (50). Analysis of this region was beyond the scope of our study, although [ 18 F]-FDG metabolism 377 in the PAG was modified by chronic USNS treatment. 378
We should emphasize that microPET imaging was performed at day 36 while behavioral tests were 379 carried out from day 38 to day 43, and metabolomic analyses performed after brain harvest at day 380 43. Further investigation of the effects of chronic USNS treatment on the brain is required to 381 explore potential effects and therapeutic outcomes. Stimulation of the M1 highlighted the need to 382 identify a precise threshold that does not exceed or fall short the efficient intensity. The 383 metabolomic analyses suggested that USNS did not induce excitotoxic effects on the target as 384 common inflammatory metabolites were not observed in screened regions (51, 52). Because the 385 technique does not rely on electromagnetic waves, US transducers could be associated with 386 calcium imaging without interference and adapted for fMRI to further the comprehension of its 387 mechanisms. On-line functional imaging of the brain tissue reaction to USNS could reveal if 388 specific neural populations are modulated (e.g. pyramidal/interneurons) as a function of 389 stimulation duration and intensity (34). Future research in US transmission through the human 390 skull could bring forward new findings on the effects of USNS in psychiatric disorders and its 391 potential use in regulating impaired brain networks. treatment strategies of major depression have shown limitations, such as inaccuracy and 395 invasiveness. In this study, we evaluated the potential of US neurostimulation (USNS) in an 396 unpredictable chronic mild stress (UCMS) model. In comparison to pharmacological treatment 397 (fluoxetine), the results showed that selected US application on the prefrontal cortex counteracts 398 behavioral modifications induced by the UCMS regimen and decreases anxiety-related behaviors 399 to a greater extent than classic fluoxetine treatment. Next to these effects, chronic repeated USNS 400 treatment triggered the activation of various brain regions including regions at distance from the 401 targeted zone as confirmed by microPET imaging and metabolomic analyses. These results 402 demonstrate the potential of USNS as a therapeutic tool for major depression. 403
Materials and Methods
404
Experimental layout 405
Eighty-three male BALB/cByJRj mice were obtained from Janvier Labs (Le Genest-Saint-Isle, 406
France), aged 9 weeks (29±1.5 g) at the beginning of the experiments. Animals were housed in 407 standard condition (12:12 light-dark cycle, room temperature 22±2° C, free access to food and 408 water). Thirty mice were used for setting-up optimal US neurostimulation (USNS) parameters with 409 motor response measurements, determined with: 1) electrode-free video recordings of the targeted 410 limb (n=20) and 2) electromyography (n=10). The remaining cohort (n=53) was divided in four 411 distinct treatment groups (Veh, Flx, Sham, chronic USNS) that underwent 35 days of the 412 unpredictable chronic mild stress regimen (UCMS) to induce depressive-like behaviors. Then, 413 from day 7 on, mice from the Veh (vehicle) and the Flx (fluoxetine) groups were chronically 414 treated through drinking water respectively with water alone (n=12) or 15 mg/kg fluoxetine 415 (n=12). Every day from day 29 to day 33, mice from the chronic USNS and the Sham groups were 416 either treated with repeated USNS under 1% isoflurane gaseous anesthesia (n=15) or solely 417 anesthetized (n=14). The whole cohort underwent behavioral tasks from day 38 to day 43 to test 418 for depressive-like and anxiety-related behaviors. To assess the underlying mechanisms, a subset 419 of mice (n=10/group) of the Sham and chronic USNS groups were further analyzed: at day 36 (72 420 hours past the last session of chronic USNS/Sham), chronic USNS mice were scanned with [ 18 F]-421 FDG microPET imaging and compared to Sham mice. At day 43 (10 days past the last session of 422 chronic USNS/Sham), brains were harvested to observe metabolome changes that occurred in 423 chronic USNS (n=8/group) versus Sham mice (n=8/group). Animals that went for metabolomics 424 were also scanned with microPET imaging. All experiments were compliant with Directive 425 2010/63/EU guidelines on animal ethics. 426
Brain stimulation setup 427
Ultrasound stimuli were generated using a single-element transducer focused at 65 mm (active 428 diameter of 38 mm, Imasonic, Besançon, France) with a central frequency of 500 kHz and a 429 fractional bandwidth of 58%. The generated acoustic pressures were measured in a degassed water 430 tank using a calibrated hydrophone (HGL 200, ONDA, Sunnyvale, CA, USA) positioned at the 431 focus. The attenuation coefficient of mice skulls (n=7) was estimated ex-vivo using standard 432 through-transmission insertion loss techniques (53). Briefly, the skull was placed along the 433 ultrasound beam between the source transducer and the hydrophone. At 500 kHz, the attenuation 434 coefficient was 6.32±2.18% (mean±SD). This coefficient was used to assess the derated acoustic 435 pressure inside the brain during US stimulation assuming the attenuation in the mouse brain tissue 436 is negligible. 437
The transducer was positioned on the mouse brain with an appended plastic column, filled with 438 degassed water. A distal collimator of 10 mm was sealed with polyethylene and coupled with 439 centrifuged US gel to the shaved cranium of the animal. Throughout all US-related procedures, 440 mice were anesthetized with 1.8 liters per minute gaseous isoflurane (2.5% induction, 1% 441 maintenance or 0.1% maintenance for electrode-free M1 stimulation; halogenated ether, Aerrane, 442
Baxter SAS), placed in a stereotaxic frame (SM-6M-HT, Narishige), the head fixed with auxiliary 443 ear bars (EB-5N, Narishige), while the transducer column was operated by a custom-made 3-axis 444 stereotaxic manipulator (27). Electrical signal was generated from a function generator (Agilent,  445 Santa Clara, CA, USA) and then amplified using a power amplifier (500W ADECE, Artannes sur 446 Indre, France; Figure 1A) . 447 c-Fos activity patterns associated to a USNS or Sham, ubiquitous sections were picked for the 477 olfactory areas (OL), which are paramount to behaviors in rodents, the auditory cortex (Ad) (36, 478 37), and frontal/prefrontal structures that lay under the US beam or its direct vicinity: the prelimbic 479 cortex (PrL), the infralimbic cortex (IL), the anterior cingulate cortex (Cg), the primary motor 480 cortex (M1) and the secondary motor cortex (M2). Furthermore, subcortical regions connected to amygdala (BLA) and central amygdala (CeA), and 2) the dorsal/ventral hippocampus 483 (dHipp/vHipp) and its subfields: the dentate gyrus (DG), the CA3 and the CA1. The number of c-484 Fos+ cells in each region of interest was expressed as normalized cellular densities (c-Fos+ 485 cells/mm²) ( Supplementary A) . 486
EMG recordings 448
Unpredictable chronic mild stress 487
The main cohort of fifty-three mice followed the UCMS regimen from day 0 to day 35 (Figure  488 3A), as described previously (54). Briefly, mice were isolated in 24×11×12 cm cages without 489 environmental enrichment and submitted to daily random socio-environmental stressors including 490 exposition to another mouse bedding, removal of sawdust, contention and light-dark cycle 491 perturbations. 492
Treatments 493
Pharmacological treatments (15 mg/kg fluoxetine) were given from day 7 on to achieve chronic 494 administration at week 5 during analyses. Short delays were described before (30) and allow to 495 observe positive effects of the drug in the experimental timespan. At week 1 of UCMS, the coat 496 state, a standard measure of general deterioration due to UCMS, was significantly deteriorated 497 compared to non-stressed mice and UCMS mice were semi-randomly divided into the four 498 treatment groups (Veh, Flx, Sham, chronic USNS; Supplementary C). The chronic repeated USNS 499 treatment was given during the fifth week of the UCMS (stressors: 08:00 -12:00 AM, treatment: 500 starting at 02:00 PM). To perform chronic USNS, another function generator (Agilent, City, CA, 501 USA), called external trigger (Figure 2A) , was used to control the repetition rate of the US stimulus 502 defined in the motor cortex stimulation procedure. A 5 Vpp square wave, set to 0.1 Hz, was used 503 to trigger the main function generator, set for 80,000 cycles (160-msec pulse) of a sine wave (500 504 kHz). The pattern was repeated for 10 min (60 US stimuli) every 10 sec (0.1 Hz); higher repetition 505 frequencies were reported to blunt cortical response (16). This constituted one treatment session 506 of chronic USNS (or "acute USNS"); one session was applied every day for 5 consecutive days 507 from day 29 to day 33 to constitute the chronic protocol of chronic USNS (total of 300 US stimuli 508 over 60 min). Through stereotaxic framing, the collimator was positioned along the 509 interhemispheric line (midline) at bregma +2 mm, a region that comprises the infralimbic cortex 510 (IL), the rodent's equivalent of the sgACC connectivity-wise (17). 511 512
Behavioral Measures 513
Behaviors were assessed during the dark phase of the light-dark cycle, i.e. the active, awoken phase 514 for the animals. The effects of USNS were assessed against those of the fluoxetine treatment from 515 day 38 to day 43 with 1) the nest-building test (55), 2) the reward-maze test (30) and 3) the open-516 field task. 517 1. For the nest-building task, mice were moved on day 37 to Makrolon type III cages, then at 07:30 518 am of day 38, a square pressed cotton (5 cm²) was placed on the sawdust. After 5 hours in standard 519 condition, the state of the nest, built in cotton, was scored on a predefined scale (55). The mice 520 were then put back in their smaller home cage. 521 2. To test for anhedonic traits, mice were subjected to a reward-maze test (30). The palatable value 522 of the reward was induced by giving a sample every day to the animals from week 2 to week 3. To 523 minimize environmental neophobia, mice were habituated three times to the paradigm on week 4 524 and the test was done under red light. The apparatus was made of three consecutive chambers 525 (20×20×20 cm) growing darker in color (light gray to black). Common food pellets were removed 526 from the cage lid 1 hour before the test. The mouse was placed in the light chamber and the reward 527 at the center of the black one. The consumption of the reward was measured for up to 5 min and 528 put in relation to the latency of reaching the reward, i.e. the consumption is expressed as the ratio 529 of bites taken into the reward over the time spent with the reward (300 sec minus the latency to 530 reach the reward). 531 3. To test for anxiety-related behaviors, mice were subjected to the open-field task on day 43. Mice 532 were placed in a brightly lit (200 lux) circular 33-cm wide open-field. The mobility (i.e. the time 533 spent moving in the field, expressed in seconds), the number of center-crossings (center area, d=10 534 cm) and ambulatory behaviors (expressed in heatmaps as a cumulated path) were measured for up 535 to 5 min. For the latter, the movements of the mice were recorded and tracked with the software 536 EthoVision XT (Noldus Information Technology, Netherlands) to generate individual heatmaps, 537 color-coded for position frequencies over the duration of the test. 538
Brain Imaging 539
At day 36, awake mice were injected with [ 18 F]-FDG (18.5 MBq/100g i.p.; Cyclopharma, Tours, isoflurane 4% (Baxter, Maurepas, France), placed on a heating pad (Minerve, Esternay, France) 542 and centered in the field of view of the Explore VISTA-CT microPET camera (GE Healthcare, 543 Velizy, France). A CT-scan was performed for attenuation correction of PET images and a list-544 mode PET acquisition of 30 min started 60 min after [ 18 F]-FDG injection. After data reconstruction 545 using a 2-D OSEM algorithm, all images were co-registered and normalized for tissue activity in 546 the whole brain. Quantitative results were expressed as mean±SD and were presented on Z-score 547 maps using an array of regions of interest already defined in PMOD v3.2 software (PMOD 548 Technologies Ltd, Switzerland). 549
During the experiments, the respiratory rate and body temperature of each animal were monitored 550 and kept as constant as possible (70 respirations per minutes and 37°C, respectively). List-mode 551 scans were rebinned into 6 frames of 300 sec, corrected for random, scatter and attenuation, and 552 images were reconstructed using a 2-D OSEM algorithm (GE Healthcare, Velizy, France) into 553 voxels of 0.3875×0.3875×0.775 mm 3 . Data summed over the entire acquisition were used for 554 image registration. Since brain anatomy is very similar for mice of similar weight (56), registration 555 was accomplished as a rigid body transformation, with no warping or scaling. Each summed scan 556 was individually smoothed with a Gaussian filter to improve the signal-to-noise ratio and to reduce 557 the bias of misregistration into template space. For this smoothing, a kernel of 0.6×0.6×0.6 mm 3 558 FWHM was used. Each scan was coregistered using PMOD v3.2 software (PMOD Technologies 559 Ltd, Switzerland) to a [ 18 F]-FDG PET template in Paxinos coordinates (57) using a mutual 560 information similarity function with Powell's convergence optimization method (58) . The results 561 were visually checked for misregistration. Each summed image was also used for statistical 562 analysis. The regions of interest (ROI) atlas of Mirrione in Paxinos coordinates were merged to 563 create a whole brain mask (WBM). To normalize the [ 18 F]-FDG uptake, tissue activity was divided 564 by the whole brain activity, calculated as the average activity in the WBM. Prior to statistical 565 analysis, the WBM was applied over all PET scans to exclude extracerebral regions. The signals 566 extracted using the ROIs on the Z-score maps were considered for further analysis when 567 representing at least 50 contiguous voxels for a statistical threshold set at p<0.05. tissue by two successive extractions, after homogenization, with a mixture of methanol/water (1/1, 572 0.75 mL). After centrifugation, the supernatant was collected, and the solvent evaporated by means 573 of a speedvac. The dry residues were finally taken up in 150 µL of MeOH/H2O (1/1). 10 µL 574 extracts of each sample were pooled to obtain a mixture used as a quality control. Finally, 20 µL 575 were used for LC-HRMS analysis. Fifteen quality control (QC) samples were injected to 576 equilibrate the chromatographic system before each analyses batch. The running order of samples 577 was randomized, and QCs were analyzed every 10 samples. The autosampler temperature 578 (Ultimate WPS-3000 UHPLC system, Dionex, Germany) was set at 4° C and the injection volume 579 for each sample was 5 µL. 580
For the chromatographic part (UPLC Ultimate WPS-3000 system Dionex, Germany), we used a 581 During the full-scan acquisition, which ranged from 58 to 870 m/z, the instrument operated at a 70 590 000 resolution (m/z=200), with an automatic gain control (AGC) target of 1×10 6 charges and a 591 maximum injection time (IT) of 250 msec. A systematic search for metabolites contained in a 592 library of standard compounds (Mass Spectroscopy Metabolite Library of MSML ® Standards, 593 IROA Technologies™) was performed. In order to validate the identity of each detected analysis were combined to provide a non-redundant list of metabolites useful for statistical 602 analysis. Metabolites with relative standard deviation (RSD) in QCs higher than that in samples 603 were excluded. Only metabolites with RSD in QCs below 30 % and identified in samples were 604 kept for further analysis. Metabolites greater than 30 % variance in QCs were not considered, 605 except if significant variance was observed between groups, meaning that biological variability 606 may exceed analytical variability (59). 607
Statistical Analysis 608
On the evaluation of motor success during single-pulse USNS, data was fit into a sigmoidal curve 609 using a Boltzmann equation (34) of the form: 610
where Omax is the highest output (set at 10) and Omin the barest (set at 0), I0 is the input half-612 maximal value and dI the slope. 613
On the evaluation of the most effective pressure step above the motor threshold, a repeated measure 614 1-way analysis of variance (ANOVA) was performed with corrected multiple comparisons (post-615 hoc Tukey). Coefficient of variation (relative standard variation, RSD) were computed for each 616 pressure step in order to characterize high-varying distributions. 617
On the study of acute repeated USNS and c-Fos densities, repeated measures 2-way ANOVAs 618 were performed accounting for stimulation (acute USNS/Sham) and bregma with corrected 619 multiple comparisons (post-hoc Tukey). The activity index of acute USNS, that is, the relative 620 increase of c-Fos density elicited by acute USNS, was computed to provide effect sizes (difference 621 of means over standard error of the difference). 622
On the study of chronic USNS, behavioral data was processed with 1-way ANOVAs with 623 corrected multiple comparisons (post-hoc Tukey). Naive mice (non-stressed, untreated) were 624 displayed as ground values and left out of the statistical analysis. 625
On the study of microPET data, a voxel-based analysis was also used to assess the differences in 626 cerebral [ 18 F]-FDG uptake between chronic USNS mice and Sham mice. The ROIs were derived 627 from Mirrione's templates (58) using PMOD v3.2 software (PMOD Technologies Ltd, considered significant when p<0.05 631
On the study of metabolomics, a first univariate statistical Mann-Withney analysis (XLSTAT) was 632 performed to select metabolites whose expression was significantly different between chronic 633 USNS mice and Sham mice. Next, metabolites whose expression ratios (fold change: FC) between 634 chronic USNS and Sham were greater than 1.25 or less than 0.75 were selected. The pathway 635 enrichment analysis was conducted by the free web software Metaboanalyst (60) to map mouse 636 metabolic pathways corresponding to metabolites selected prior to analysis. The pathway plots 637 were based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database, and the National 638
Center for Biotechnology Information (NCBI) database was searched to define gene functions. 639
Only the metabolic pathways for which the FDR (false discovery rate) corrected statistics is 640 significant were retained for discussion. 641 counted in the granular layer of the dentate gyrus in 8 ubiquitous sections along the anteroposterior axis of the brain. Cells counts were expressed as cellular densities (/mm²). For ground values, scores of mice that were treated either with fluoxetine or vehicle were added (the mice followed the same UCMS regimen and displayed similar results and significance in the behavioral tasks described in the main study, n=5/group).
The analysis revealed no difference between chronic USNS and Sham mice ( Supplementary   Figure 2 ). Despite an immediate effect of a USNS on c-Fos densities in the hippocampus and the modification of metabolic pathways in the hippocampus following chronic USNS, proliferation mechanisms in the dentate gyrus were not readily engaged in the present case. Because neurogenesis has been associated to antidepressant effects (1), the fact that USNS does not promote the proliferation of newborn neurons could be associated to the lack of effects on depressive-like behaviors at this epoch, measured in the reward-maze test. Independently, mice treated with fluoxetine (Flx) displayed higher DCX+/Ki67+ densities in comparison to vehicle mice (t(8)=4.1, p=0.0035). 
Supplementary C. Coat state at day 7
Comparison of coat states with non-stressed mice (NS, n=48), no difference in terms of age or weight from the UCMS mice of the main cohort (n=53). Treatment groups for UCMS (Veh, Flx, Sham, chronic USNS) were determined at day 7 (semi-randomization of mice according to coat states). UCMS deteriorated significantly the coat state at day 7, marking the onset of the UCMS regimen (t(99)=23, p<0.0001; Supplementary Figure 3 ). Figure 3 . NS: non-stressed, UCMS: unpredictable chronic mild stress. Data expressed as mean ± SEM. **** p<0.0001.
Supplementary
